The Patent Finder

Beijing Protgen Ltd.

3 patents currently held · Updated Nov 21, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 21, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 3 of 3

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,364,493Methods and Compositions for Enhancing the Uptake of Therapeutic Agents by Target Cells
In force
 · High confidence
In forceHigh confidence
US 10,869,910Molecular Design of Recombinant Protein Drug
In force
 · Medium confidence
In forceMedium confidence
US 11,098,104Pegylated Endostatin Analogue and Application Thereof
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 3: 2 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

8 abandoned

Showing 1 to 8 of 8, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.

ApplicationTitleFiledStatus
18/512,519Medication for Inhibiting Dna-PkcsNov 17, 2023Abandoned
17/869,348Drug for Inhibiting Adipose Cell Differentiation and Insulin ResistanceJul 20, 2022Abandoned
17/035,497Molecular Design of Recombinant Protein DrugSep 28, 2020Abandoned
16/635,006Medication for Inhibiting Dna-PkcsJul 27, 2018Abandoned
15/842,231Method for Inhibiting Lymphangiogenesis by Administration of an Inhibitor of the CXCL12 PathwayDec 14, 2017Abandoned
15/524,094Drug for Inhibiting Adipose Cell Differentiation and Insulin ResistanceNov 3, 2015Abandoned
14/901,509Tumor BiomarkerJun 27, 2014Abandoned
13/962,111Method and Medicament for Inhibiting LymphangiogenesisAug 8, 2013Abandoned
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited